Photo News-信达生物 Mediaroom

信达生物

Photo News

$Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at 2019 ASCO and EHA Annual Meetings$

Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at 2019 ASCO and EHA Annual Meetings

2019-06-18 08:00 4766

Innovent Receives IFR Asia-Pacific IPO of the Year 2018 and IFR Asia Review Hong Kong Equity Issue of the Year 2018 Awards

2019-02-27 12:00 773

China's NMPA Approves Innovent's Anti-PD-1 Antibody Tyvyt® (Sintilimab injection) for Hodgkin's Lymphoma

2018-12-27 16:45 2093